<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND AIM: The <z:chebi fb="0" ids="35666">thiopurines</z:chebi> <z:chebi fb="2" ids="2948">azathioprine</z:chebi> and <z:chebi fb="1" ids="50667">6-mercaptopurine</z:chebi> are effective in the management of patients with <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD) in whom aminosalicylates, antibiotics and <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> have failed to induce or maintain remission </plain></SENT>
<SENT sid="1" pm="."><plain>Long-term use of these agents has been linked to a greatly increased risk of non-<z:hpo ids='HP_0002861'>melanoma</z:hpo> <z:e sem="disease" ids="C0007114" disease_type="Neoplastic Process" abbrv="">skin cancer</z:e> and <z:e sem="disease" ids="C0920571" disease_type="Neoplastic Process" abbrv="">lymphatic cancer</z:e> in organ transplant recipients </plain></SENT>
<SENT sid="2" pm="."><plain>There is some evidence to suggest that IBD patients receiving <z:chebi fb="0" ids="35666">thiopurines</z:chebi> might be at increased risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Our aim was to determine the incidence of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in a cohort of patients with IBD managed in our clinic, and to relate this to <z:chebi fb="0" ids="35666">thiopurine</z:chebi> exposure </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: We conducted a retrospective study based on the clinical and pathology records of patients attending a specialist IBD clinic at Groote Schuur Hospital, Cape Town, South Africa between 1960 and 2007 </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: We analyzed the records of 1084 patients </plain></SENT>
<SENT sid="6" pm="."><plain>A total of 123 subjects (11.5%) had received <z:chebi fb="0" ids="35666">thiopurine</z:chebi> therapy </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> was identified in 51 patients (4.7%), including <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (15 patients), <z:hpo ids='HP_0002861'>melanoma</z:hpo> (two patients), non-<z:hpo ids='HP_0002861'>melanoma</z:hpo> <z:e sem="disease" ids="C0007114" disease_type="Neoplastic Process" abbrv="">skin cancer</z:e> (seven patients) and non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (five patients) </plain></SENT>
<SENT sid="8" pm="."><plain>A diagnosis of non-<z:hpo ids='HP_0002861'>melanoma</z:hpo> <z:e sem="disease" ids="C0007114" disease_type="Neoplastic Process" abbrv="">skin cancer</z:e> was significantly associated with <z:chebi fb="0" ids="35666">thiopurine</z:chebi> exposure (odds ratio 5.0, 95% confidence interval 1.1-22.8) </plain></SENT>
<SENT sid="9" pm="."><plain>Six of seven non-<z:hpo ids='HP_0002861'>melanoma</z:hpo> <z:e sem="disease" ids="C0007114" disease_type="Neoplastic Process" abbrv="">skin cancers</z:e> occurred in Caucasian patients, with a highly significant association with <z:chebi fb="0" ids="35666">thiopurine</z:chebi> use (odds ratio 12.4, 95% confidence interval 2.3-67.4) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Patients with IBD who receive <z:chebi fb="0" ids="35666">thiopurines</z:chebi> are at increased risk of non-<z:hpo ids='HP_0002861'>melanoma</z:hpo> <z:e sem="disease" ids="C0007114" disease_type="Neoplastic Process" abbrv="">skin cancer</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>The risk is highest in Caucasian patients, and is negligible in other groups </plain></SENT>
</text></document>